Page 3 - Serum Institute Of India

DCGI approves India's first qHPV vaccine to treat cervical cancer

SII's CEO Adar Poonawalla tweeted to make the announcement, 'For the first time, there will be an Indian HPV vaccine to treat cervical cancer in women that is both affordable and accessible'

SII gets govt nod to export 3.24 mn doses of Covovax vaccine to US

COVID-19 jab Covovax will be the first vaccine to be exported to the country, under the brand name Nuvaxovid, by any Indian manufacturer, official sources said on Friday

SII's Covovax gets DCGI's nod for emergency use in children aged 7-11 yrs

The DCGI's nod came after the subject expert committee on COVID-19 of the CSDCO last week recommended granting emergency use authorisation to Covovax for the age group of 7 to 11 years

Expert panel approves use of Serum Institute's Covovax for 7-11-year olds

India started vaccinating adolescents (aged 15-18) from January, and further expanded the drive to include children as young as 12 years from March

DCGI panel to review on Friday SII applications for Covovax use among kids

The expert panel in its last meeting in April had sought more data from SII following its application seeking the emergency use authorization of Covovax for seven to 11 years

Hundreds of millions of Covid vaccines in India to expire in September

Covaxin has a shelf life of 12 months, while Covishield, the vaccine that accounted for nearly 80% of India's vaccinations, has a shelf life of nine months

India's Serum Institute to make Novavax's Covid vaccine for US market

The company has indicated in the first quarter earnings call that it has reached a major milestone in its pathway to an emergency use authorisation from the US Food and Drugs Administration

Covid vaccine for US to be manufactured by India's Serum, says Novavax

Novavax Inc said on Tuesday that its Covid-19 vaccine initially available in the United States, if authorized, will be manufactured by the Serum Institute of India.

Covid-19 vaccine: SII to test Novavax for Omicron variant strain

The Pune-based company has also got a nod from the Indian drug regulator's office to manufacture trial batches of this vaccine for the purpose of testing, sources indicated.

Serum Institute likely to launch cervical cancer vaccine in India in Nov

Country now depends on foreign companies and Serum's product is likely to bring down prices.

Use Covid learning to boost global health: Adar Poonawalla to world leaders

Serum Institute of India (SII) CEO Adar Poonawalla on Monday said he is appealing to multilateral organisations and world leaders to come up with a draft about learnings from the COVID-19 pandemic to strengthen health systems globally. The learnings from the global pandemic would help in addressing inequity in the health systems that are prevalent currently, Poonawalla said. "This year @Davos, I am appealing to multilateral organisations & world leaders to come together in creating a draft, learning from the lessons of the pandemic for a Global Pandemic Treaty to address inequity & strengthen global health systems," he tweeted. Pune-based SII is the world's largest vaccine manufacturer by the number of doses produced and sold globally. During the pandemic, the company not only supplied COVID-19 vaccines in India but also exported these to multiple nations.

Cyrus Poonawalla gets top Johns Hopkins honour for developing Covid vaccine

The SII, with its Covid-19 vaccines, played a huge role in fighting the Coronavirus pandemic that raged across the world in the past over two years.

SII seeks permission for trial of Covovax as booster for ages 2 to18 yrs

SII has sought permission from country's drug regulator to conduct Phase-3 trial to evaluate safety and immunogenicity of its COVID vaccine Covovax as a booster dose in children aged two to 18 years

CCI approves Serum Institute Life Sciences-Biocon Biologics deal

The Competition Commission of India (CCI) has approved a proposed deal involving Serum Institute Life Sciences, Covidshield Technologies and Biocon Biologics. Once the deal is complete, Serum Institute Life Sciences Pvt Ltd will have about 15 per cent stake in Biocon Biologics Ltd, according to the notice filed with the regulator. Covidshield Technologies Pvt Ltd (CTPL), a wholly-owned subsidiary of Serum Institute of Life Sciences, will be merged into Biocon Biologics. In a tweet on Wednesday, the watchdog said it has cleared the "merger by absorption of Covidshield Technologies into Biocon Biologics in consideration for acquisition of approximately 15 per cent equity shareholding of Biocon Biologics by Serum Institute Life Sciences." CTPL was incorporated to undertake the business of marketing, selling and distributing vaccines, drugs and other pharmaceutical products. Biocon Biologics Ltd is a subsidiary of Biocon Ltd. It offers treatment for chronic and acute diseases such as

Adar Poonawalla woos Musk to invest in making Tesla cars in India

Serum Institute of India (SII) CEO Adar Poonawalla on Sunday wooed Elon Musk to invest in India to manufacture Tesla electric cars, saying it will be the best investment he would have ever made.

Covid vaccine Covovax available for all above 12 years: Adar Poonawalla

"A lot of you have asked if Covovax is available for adults. The answer is yes, it is available for everyone above the age of 12," CEO of Serum Institute of India Adar Poonawalla tweeted

SII lowers each dose of Covovax jab from Rs 900 to Rs 225 excluding taxes

A day after its Covid shot Covovax was included on the CoWIN portal for inoculation of children aged 12-17 years at private vaccination centres, the Serum Institute of India (SII) on Tuesday reduced the price of each dose of the vaccine from Rs 900 to Rs 225, excluding taxes. Following recommendation of the National Technical Advisory Group on Immunisation (NTAGI) the provision of the vaccine option was included on the portal on Monday. On Tuesday, Director for Government and Regulatory Affairs, SII, Prakash Kumar Singh, is learnt to have communicated to the government that the firm is reducing the price of each dose from Rs 900 to Rs 225 plus goods and services tax (GST) for private hospitals. In addition, a private hospital can charge up to Rs 150 as service charge. The price of the vaccine, Covovax, is learnt to have been revised on the CoWIN portal. India's drug regulator had approved Covovax for restricted use in emergency situations in adults on December 28 last year and in t

Covovax now available for children in India: SII CEO Adar Poonawalla

Serum Institute of India (SII) CEO Adar Poonawalla on Tuesday said that the Covid-19 vaccine Covovax is now available in India for children.

NTAGI meet this week to review vaccine data for 5-12 age group

A senior government official had told Business Standard last week that so far there was no scientific evidence to expand the vaccination programme to young children

SII's Covovax vaccine now available for 12-17 age group at private centres

A dose of Covovax will cost Rs 900 plus GST, in addition to hospital service charge of Rs 150, official sources told PTI